Drug intelligence / Profile preview

CYAD-231

Development stage: Preclinical
Lead developer: Celyad Oncology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CYAD-231 is a preclinical allogeneic chimeric antigen receptor (CAR) T-cell therapy candidate being developed by Celyad Oncology for the treatment of cancer, leveraging the company’s expertise in NKG2D-based CARs and allogeneic cell engineering. Public disclosures list CYAD-231 among Celyad’s next-generation pipeline assets but do not yet provide detailed target or construct information, other than indicating it is distinct from earlier candidates such as CYAD-01, CYAD-101, CYAD-02, CYAD-103, CYAD-203, CYAD-211, and CYAD-221.[7][12][9] CYAD-231 remains in the IND-enabling/preclinical research stage with no active clinical trials reported.

Targets

MICB (Major histocompatibility complex class i-related protein B)

Beyond the preview

Go deeper on CYAD-231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYAD-231.

Explore the full profile